DE69701458T2 - Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen - Google Patents

Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen

Info

Publication number
DE69701458T2
DE69701458T2 DE69701458T DE69701458T DE69701458T2 DE 69701458 T2 DE69701458 T2 DE 69701458T2 DE 69701458 T DE69701458 T DE 69701458T DE 69701458 T DE69701458 T DE 69701458T DE 69701458 T2 DE69701458 T2 DE 69701458T2
Authority
DE
Germany
Prior art keywords
buckminsterfulleren
neurotoxic injuries
treating neurotoxic
treating
injuries
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69701458T
Other languages
English (en)
Other versions
DE69701458D1 (de
Inventor
Wonkyu Choi
Laura Dugan
Tom Linn
Tien-Yah Luh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE69701458D1 publication Critical patent/DE69701458D1/de
Publication of DE69701458T2 publication Critical patent/DE69701458T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69701458T 1996-06-03 1997-05-26 Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen Expired - Lifetime DE69701458T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1889996P 1996-06-03 1996-06-03
PCT/EP1997/002679 WO1997046227A1 (en) 1996-06-03 1997-05-26 The use of buckminsterfullerene for treatment of neurotoxic injury

Publications (2)

Publication Number Publication Date
DE69701458D1 DE69701458D1 (de) 2000-04-20
DE69701458T2 true DE69701458T2 (de) 2000-09-07

Family

ID=21790333

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69701458T Expired - Lifetime DE69701458T2 (de) 1996-06-03 1997-05-26 Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen

Country Status (16)

Country Link
EP (1) EP0904070B1 (de)
JP (1) JP2000514412A (de)
KR (1) KR20000016238A (de)
CN (1) CN1221340A (de)
AR (1) AR007369A1 (de)
AT (1) ATE190486T1 (de)
AU (1) AU720528B2 (de)
BR (1) BR9709636A (de)
CA (1) CA2255913C (de)
DE (1) DE69701458T2 (de)
DK (1) DK0904070T3 (de)
ES (1) ES2145608T3 (de)
GR (1) GR3033646T3 (de)
PT (1) PT904070E (de)
TR (1) TR199802504T2 (de)
WO (1) WO1997046227A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6538153B1 (en) 2001-09-25 2003-03-25 C Sixty Inc. Method of synthesis of water soluble fullerene polyacids using a macrocyclic malonate reactant
US7145032B2 (en) 2002-02-23 2006-12-05 Washington University Therapeutic malonic acid/acetic acid C60 tri-adducts of buckminsterfullerene and methods related thereto
US20030162837A1 (en) * 2002-02-23 2003-08-28 Dugan Laura L. Carboxyfullerenes and methods of use thereof
WO2004080453A1 (ja) 2003-03-10 2004-09-23 Mitsubishi Corporation 抗c型肝炎ウイルス剤と抗hiv剤
EP1615609A2 (de) * 2003-04-10 2006-01-18 C Sixty, Inc. Fulleren-zusammensetzungen zur linderung von dermatologischen erkrankungen
US7163956B2 (en) * 2003-10-10 2007-01-16 C Sixty Inc. Substituted fullerene compositions and their use as antioxidants
WO2006028635A2 (en) * 2004-09-02 2006-03-16 C Sixty Inc. Fullerene compositions for ameliorating hearing loss, collateral damage of chemotherapy, or mucositis
JP6471288B2 (ja) * 2014-12-19 2019-02-20 昭和電工株式会社 フラーレン組成物、樹脂添加剤および樹脂組成物
TWI704127B (zh) * 2017-03-16 2020-09-11 國立臺灣大學 富勒烯衍生物及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996036631A1 (en) * 1995-05-19 1996-11-21 Sphere Biosystems, Inc. Multiply-substituted fullerenes and methods for their preparation and characterization

Also Published As

Publication number Publication date
CA2255913C (en) 2007-07-31
EP0904070B1 (de) 2000-03-15
PT904070E (pt) 2000-08-31
DE69701458D1 (de) 2000-04-20
GR3033646T3 (en) 2000-10-31
ES2145608T3 (es) 2000-07-01
AU3167297A (en) 1998-01-05
WO1997046227A1 (en) 1997-12-11
KR20000016238A (ko) 2000-03-25
CA2255913A1 (en) 1997-12-11
ATE190486T1 (de) 2000-04-15
AR007369A1 (es) 1999-10-27
BR9709636A (pt) 1999-08-10
CN1221340A (zh) 1999-06-30
TR199802504T2 (xx) 1999-03-22
AU720528B2 (en) 2000-06-01
DK0904070T3 (da) 2000-06-26
JP2000514412A (ja) 2000-10-31
EP0904070A1 (de) 1999-03-31

Similar Documents

Publication Publication Date Title
DE69722681D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
DE69733329D1 (de) Verwendung von Taurin zur Behandlung oder Vorbeugung von ischämischen Verletzungen
DE69711067T2 (de) Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose
ATA46794A (de) Einrichtung zur behandlung von hautzonen
DE69115921D1 (de) Verfahren zur behandlung und verwendung von abfallstoffen
DE69526935T2 (de) Verwendung von mycobacterium zur tumorbehandlung
DE59707519D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE69702997T2 (de) Verfahren zur Behandlung von verunreinigtem Aluminiumoxid
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
ATE227278T1 (de) Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression
DE69701458D1 (de) Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen
DE69621447T2 (de) Verwendung von nitroflavonoide zur behandlung von angstzuständen
DE59705697D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE59704933D1 (de) Verwendung von PHMB zur Behandlung von Tumorerkrankungen
DE69706758D1 (de) Verfahren zur Behandlung von Polyolefin
DE69717846T2 (de) Behandlungsverfahren von laktamen
DE69706195T2 (de) Antikonvulsive derivate zur behandlung von psoriasis
DE69714424D1 (de) Verwendung von kolostrum zur behandlung von darmverstopfung
DE69926996D1 (de) Verwendung von riluzol zur behandlung der retinalischemie
DE59904564D1 (de) Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien
DE69819503D1 (de) Verwendung von 7-apha-methyl-17-alpha-ethynyl-estrane derivaten zur behandlung von atherosclerose
DE59712374D1 (de) Verwendung von hcc-1 zur behandlung von thrombozytopenien
DE59701111D1 (de) Verfahren zur biologisch-thermischen behandlung von abfällen
DE69302250D1 (de) Verwendung von Isoquinolinon-Derivaten zur Behandlung von Hyperlipoproteinemia

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: WASHINGTON UNIVERSITY, ST. LOUIS, MO., US